FDA Approves Cemiplimab-rwlc for NSCLC With PD-L1 Expression FDA Approves Cemiplimab-rwlc for NSCLC With PD-L1 Expression

The FDA has approved cemiplimab-rwlc as monotherapy for first-line treatment of advanced non –small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news